TOKYO, Oct. 15, 2026 /PRNewswire/ — TECHFUND, a Tokyo-based technology accelerator, announced that Hi AUDIT Agent achieved a 90.6% success rate on CyberGym, surpassing Anthropic’s published Claude Mythos 5 score by 6.8 percentage points. As an AI-powered security copilot, Hi AUDIT Agent brings specialized security analysis into developers’ existing workflows, helping teams move from identifying risks to reviewing potential fixes.
Integrating Security into Development Workflows
Hi AUDIT Agent is designed to help development teams incorporate security reviews into their daily work. It combines AI capabilities with specialized security knowledge and insights from security audits.
Through the Model Context Protocol (MCP), developers can connect Hi AUDIT to compatible AI coding tools and editors. They can request security analysis, examine findings in context and review proposed fixes within their existing workflows.
To learn more about Hi AUDIT Agent or create a free account, visithiaudit.io.
About TECHFUND
Founded in 2014 and headquartered in Tokyo, TECHFUND is a technology accelerator that supports entrepreneurs and corporate innovation teams. It has supported 500+ startup and entrepreneurial teams, as well as intrapreneurs at 50+ major companies, including Nomura Holdings, SoftBank and JCB. Its core businesses include Hi STARTUP, which combines lean startup methods with agile development to help build new ventures, and Hi AUDIT, which provides security audits across fields including AI, Web3 and IoT.
About CyberGym
CyberGym is an evaluation platform developed by a research team at the University of California, Berkeley that utilizes real-world software vulnerabilities. CyberGym requires AI agents to generate working proof-of-concept tests that reproduce a specific vulnerability in a software project. The reported success rate measures performance on these benchmark tasks.
Media contact
TECHFUND Inc.
Yu Ashino
Corporate Communications
[email protected]
ข่าวที่เกี่ยวข้อง
- World Young Scientist Summit 2026 Opens in Wenzhou, Zhejiang
- The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
- Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
- 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
